Pre-made Technetium (99Mtc) Nofetumomab Merpentan benchmark antibody (Radiolabelled antibody, anti-MS4A1/CD20 therapeutic antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Anti-MS4A1/CD20 therapeutic antibody (Pre-made Technetium (99Mtc)
Nofetumomab Merpentan biosimilar, Radiolabelled antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Technetium (99mTc) nofetumomab merpentan (trade name Verluma) is a mouse monoclonal antibody derivative used in the diagnosis of lung cancer,[1] gastrointestinal, breast, ovary, pancreas, kidney, cervix, and bladder carcinoma.[2] The antibody part, nofetumomab, is attached to the chelator merpentan, which links it to the radioisotope technetium-99m (99mTc).[3]
| Products Name (INN Index) | Pre-Made Technetium (99Mtc) Nofetumomab Merpentan Biosimilar, Radiolabelled Antibody: Anti-MS4A1/CD20 therapeutic antibody |
|---|---|
| INN Name | technetium (99mTc) nofetumomab merpentan |
| Target | MS4A1 |
| Format | Radiolabelled antibody |
| Derivation | Mus musculus |
| Species Reactivity | Human |
| CH1 Isotype | Fab – G2b – kappa |
| VD LC | Fab – G2b – kappa |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | NeoRx?Corp. (Seattle WA USA) / Boehringer Ingelheim Pharmaceuticals (Ridgefield CT USA) / DuPont?Merck Pharmaceutical (Billerica MA USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | MS4A1 |
| Package |
